It is an apples-to-apples comparison in the sense of trial design of nuke + ribavirin for 12 weeks dosing in GT1 patients. There were probably differences between patient populations, but RVR can give a better parameter to compare efficacy than PK, as VRTX tried to sell on their CC. So, VX-135 would seem to be a weaker nuke than sofosbuvir and yes it could still work out in a stronger combo but unlikely in shorter dosing period of time.
Market Data 
Markets 
AI
